<SEC-DOCUMENT>0001213900-23-051549.txt : 20230626
<SEC-HEADER>0001213900-23-051549.hdr.sgml : 20230626
<ACCEPTANCE-DATETIME>20230626080302
ACCESSION NUMBER:		0001213900-23-051549
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230626
FILED AS OF DATE:		20230626
DATE AS OF CHANGE:		20230626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		231039460

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea180897-6k_enlivextherap.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED
STATES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
AND EXCHANGE COMMISSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
6-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
of Foreign Private Issuer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 13a-16 or 15d-16</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of: June 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-36578</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ENLIVEX
THERAPEUTICS LTD.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>14
Einstein Street, Nes Ziona, Israel 7403618</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&#9744;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 26, 2023, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the &ldquo;Company&rdquo;), issued
a press release announcing its financial results for the first quarter ended March 31, 2023 and the prior filing on June 16, 2023 with
the Securities and Exchange Commission of the Company&rsquo;s unaudited condensed consolidated financial statements, as of and for the
three month periods ended March 31, 2023 and 2022 and related management&rsquo;s discussion for such periods. A copy of such press release
is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="ea180897ex99-1_enlivextherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Enlivex Therapeutics Ltd. on June 26, 2023.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURES</U></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex
    Therapeutics Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oren Hershkovitz</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren
    Hershkovitz<BR>
    Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
June 26, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea180897ex99-1_enlivextherap.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON JUNE 26, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Enlivex Announces First Quarter 2023 Financial
Results and Provides a Business Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Enrollment of patients in the Phase I/II evaluating Allocetra&trade; in combination with chemotherapy in patients with peritoneal
metastases from advanced solid tumors is proceeding as planned, with 50% (lower dose cohorts) already enrolled.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The integration of tislelizumab, an anti-PD-1 immune checkpoint inhibitor, into the ongoing Phase I/II clinical trial, evaluating
Allocetra&trade; as monotherapy and in combination with anti-PD1 checkpoint inhibitors in patients with advanced-stage and solid tumors,
is progressing. First patient enrolled pursuant to the amended protocol is expected by end of Q3 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Obtained clearance from the regulatory authority in Spain to open recruitment of patients in Spain into an ongoing Phase I/II clinical
trial, evaluating Allocetra&trade; as monotherapy and in combination with anti-PD1 checkpoint inhibitors in patients with advanced-stage
solid tumors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Obtained approval from regulatory authorities in the Netherlands, and awaiting approval in additional countries, for amendments to
the protocol of the Company&rsquo;s ongoing Phase II trial evaluating Allocetra&trade; in patients with sepsis. More than 50% of the patients
in the study have been enrolled to date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nes-Ziona, Israel, June 26, 2023 (GLOBE NEWSWIRE)
-- </B>Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;), a clinical-stage macrophage reprogramming immunotherapy
company, on June 16, 2023, filed with the SEC its financial results and related management&rsquo;s discussion for the first quarter ended
March 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>First Quarter 2023 Financial Results:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $5.2 million for the three months
ended March 31, 2023, as compared to $4.7 million for the same period in 2022. The increase of 11% was primarily due to an increase in
expenses for clinical studies and pre-clinical studies, offset by a decrease in lease payments and overhead expenses related to our plant
space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">General and administrative expenses were $1.6
million for the three months ended March 31, 2023, as compared to $1.7 million for the same period in 2022. The decrease of 7% was primarily
due to decrease in stock-based compensation expense with respect to equity granted to employees and directors, and decrease in professional
fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net loss for the three months ended March 31, 2023 was $7.2 million,
as compared to a net loss of $8.2 million for the three months ended March 31, 2022. This decrease resulted primarily from a decrease
in other expenses, net, which was partially offset by an increase in the costs of clinical and pre-clinical studies and material consumption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2023, Enlivex had cash and cash equivalents, short
term bank deposits and long term interest-bearing bank deposits of $43.2 million. The Company believes its existing cash and cash equivalents
will be sufficient to fund its operating expenses and capital expenditure requirements potentially into 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT ALLOCETRA&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Allocetra&trade; is being developed as a universal, off-the-shelf cell
therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram
macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective
diseases. By restoring macrophage homeostasis, Allocetra&trade; has the potential to provide a novel immunotherapeutic mechanism of action
for life-threatening clinical indications that are defined as &ldquo;unmet medical needs&rdquo;, as a stand-alone therapy or in combination
with leading therapeutic agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT ENLIVEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Enlivex is a clinical stage macrophage reprogramming
immunotherapy company developing Allocetra&trade;, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their
homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution
of life-threatening conditions. For more information, visit <U STYLE="text-decoration: none">http://www.enlivex.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Safe Harbor Statement:&nbsp; This press
release contains forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo;
&ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo; &ldquo;would&rdquo;, &ldquo;could,&rdquo;
&ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;has the potential to&rdquo; and other words of similar
meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical
experiments, the effectiveness of, and market opportunities for, ALLOCETRA<SUP>TM</SUP>&nbsp;programs. All such forward-looking statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.&nbsp; Investors are cautioned
that forward-looking statements involve risks and uncertainties that may affect&nbsp;Enlivex&rsquo;s&nbsp;business and prospects, including
the risks that&nbsp;Enlivex&nbsp;may not succeed in generating any revenues or developing any commercial products; that the products in
development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval
or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show
substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of
clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage
trials. The development of any products using the ALLOCETRA<SUP>TM</SUP>&nbsp;product line could also be affected by&nbsp;a number of&nbsp;other
factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making,
the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary
rights held by competitors and other third parties.&nbsp; In addition to the risk factors described above, investors should consider the
economic, competitive, governmental,&nbsp;technological&nbsp;and other factors discussed in&nbsp;Enlivex&rsquo;s&nbsp;filings with the
Securities and Exchange Commission, including in the Company&rsquo;s most recent Annual Report on Form 20-F filed with the Securities
and Exchange Commission.&nbsp; The forward-looking statements contained in this press release speak only as of the date the statements
were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>ENLIVEX CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B></B>Shachar Shlosberger, CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Enlivex Therapeutics, Ltd.<BR>
<U STYLE="text-decoration: none">shachar@enlivexpharm.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR RELATIONS CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eric Ribner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U STYLE="text-decoration: none">eric@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !^ ,D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHIDDB11L[L%51DD]A0W8!],DFCB7=(ZH/5CBN7N?$=W?S
MM;:/ S=O-(_7V_&DB\+W5XWFZI>NS'^%3G'XUQ/%.;M1CS>>R,^>_P *.B&H
MV;'"W<)/^^*L*P90P((/<5SS>#=/*X62=3ZY!_I5"?2]4T$&XL;EIH%Y9#Z>
MXJ77K0UJ0T\F'-);H[*BLS1]7AU6VWIA95^_'GI_]:M.NR$XSBI1>A:::N@H
MHHJQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 !KE_%=W(_V?3(
M3\\[ MCTSP/\^E=.QPI)Z"N1T=3J_B2XU"3E(3A ?R%<6+;:5*.\ORZF<^W<
MM2ZC9^&X8[&"$S7& 7"]SZDU-IOB:*]N1;3PM;S-]T$\'VK+6:'3_&-Q)?#:
MKY*.PR!GH:;K5S;ZCK=DE@1)*K#<Z#W%<:KSCK%I).W*1S-;/Y':BD(SQ0.E
M+7L;FYR.KZ5-I-Q_:NF$JJG,D8[?_6KH-*U!-3L4N4X)X9?0]ZMR(LL;1L,J
MP((KE_";-;WU_8D\(V1^!Q_A7 H^QKI1^&73S,_AEIU.KHHHKT#0**,U&\\,
M?WY47_>8"@"2BJ$VMZ3;_P"NU2RC_P!^X0?S-9]QXY\*6O\ KO$6F ^@N5/\
MC0.QOT5QD_Q9\"V^0_B*V8CLBNW\A6;/\;_ L.<:E-+_ -<[=C_,4!9GHM%>
M53_M >#HQ^ZCU*4^T '\S53_ (:(\,_] [4O^^%_QH'ROL>P45\U7'[0WB9R
M1%IFFQ>G#-_6LR7X\>-Y,[)K&('^[; X_,TKC]G(^J**^1I_C'X[GS_Q.S'G
M_GG"@_I69/\ $GQI<?ZSQ)?G_=<+_(47*]DS[,IC2HOWG4?4U\2S>*O$5P<S
M:[J3_6Z?_&J$M]>7'^NO+B7_ 'Y6;^9HN/V3[GW!/JVG6PS/?VL7^_,H_F:S
M9_&WA:V_UWB'3%/I]J0G^=?%)Y.3S28'I1<?LO,^P[OXH^"(8W5_$EGR"/D+
M/_(5BZ=XZT'PMICW6I7+K;7+@P21QE]_'MTXKY7Q7IGADCQ5\/KW1)2&NK,9
MASUQU7]<BN+$^[*%7L]?1F56"BU(]*U7XU^ +Q LL.H7++]TI;XQ^)(K(@^.
M7A+2V+6&@Z@[GC<[*#_,UX"RLC%74JRD@@]C25T>S@Y<]E<U5&&Y[[/^TA!C
M_1_#DN?^FEP/Z"LZ7]H_4S_J?#UHO^_.Q_D*\3HK2Y?LXGL,/QW\9:K>Q6=A
MI^FI-,P5!Y;-_6K7C3XA:SX8N+==-NX5U2X4O=.(@1CV!Z9-<K\+[.))=3UB
M50?LL6U">Q()/Z 5Q&IZC/JVI3WURVZ69BQ]AV'X5QO][7\H?FS#E4JENB.M
ME^+_ ([ES_Q/I$S_ '(D']*SI_B+XRN,^9XDU'G^[+M_EBN9HKL.GE78U)O$
MFNW))GUO4I<]=]TY_K5"2YN)3F2XF<_[3DU%10.R \]23]:3 ]!2T4 %%%%
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M--77+U='$G]G+*5MS*VYB@X!)]^M [ZV*%%%%!04444 %%%% !1110 4444
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M!] & -K0C&W_ ($ 3^->*.CQR-'(I5T)5E(Y!'44R:8VBBBD:A1110 4444
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..BBB@H**** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
